S&P 500   2,506.22 (-3.03%)
DOW   21,334.94 (-2.66%)
QQQ   186.33 (-2.14%)
AAPL   246.71 (-2.98%)
FB   162.72 (-2.45%)
MSFT   156.29 (-0.90%)
GOOGL   1,124.77 (-3.20%)
AMZN   1,926.86 (-1.17%)
CGC   14.29 (-0.90%)
NVDA   257.99 (-2.13%)
MU   41.77 (-0.69%)
GE   7.38 (-7.05%)
TSLA   506.02 (-3.43%)
AMD   46.35 (+1.91%)
ACB   0.87 (-4.40%)
F   4.67 (-3.52%)
NFLX   370.52 (-1.33%)
BAC   20.11 (-5.28%)
GILD   73.40 (-1.83%)
DIS   95.76 (-0.87%)
S&P 500   2,506.22 (-3.03%)
DOW   21,334.94 (-2.66%)
QQQ   186.33 (-2.14%)
AAPL   246.71 (-2.98%)
FB   162.72 (-2.45%)
MSFT   156.29 (-0.90%)
GOOGL   1,124.77 (-3.20%)
AMZN   1,926.86 (-1.17%)
CGC   14.29 (-0.90%)
NVDA   257.99 (-2.13%)
MU   41.77 (-0.69%)
GE   7.38 (-7.05%)
TSLA   506.02 (-3.43%)
AMD   46.35 (+1.91%)
ACB   0.87 (-4.40%)
F   4.67 (-3.52%)
NFLX   370.52 (-1.33%)
BAC   20.11 (-5.28%)
GILD   73.40 (-1.83%)
DIS   95.76 (-0.87%)
S&P 500   2,506.22 (-3.03%)
DOW   21,334.94 (-2.66%)
QQQ   186.33 (-2.14%)
AAPL   246.71 (-2.98%)
FB   162.72 (-2.45%)
MSFT   156.29 (-0.90%)
GOOGL   1,124.77 (-3.20%)
AMZN   1,926.86 (-1.17%)
CGC   14.29 (-0.90%)
NVDA   257.99 (-2.13%)
MU   41.77 (-0.69%)
GE   7.38 (-7.05%)
TSLA   506.02 (-3.43%)
AMD   46.35 (+1.91%)
ACB   0.87 (-4.40%)
F   4.67 (-3.52%)
NFLX   370.52 (-1.33%)
BAC   20.11 (-5.28%)
GILD   73.40 (-1.83%)
DIS   95.76 (-0.87%)
S&P 500   2,506.22 (-3.03%)
DOW   21,334.94 (-2.66%)
QQQ   186.33 (-2.14%)
AAPL   246.71 (-2.98%)
FB   162.72 (-2.45%)
MSFT   156.29 (-0.90%)
GOOGL   1,124.77 (-3.20%)
AMZN   1,926.86 (-1.17%)
CGC   14.29 (-0.90%)
NVDA   257.99 (-2.13%)
MU   41.77 (-0.69%)
GE   7.38 (-7.05%)
TSLA   506.02 (-3.43%)
AMD   46.35 (+1.91%)
ACB   0.87 (-4.40%)
F   4.67 (-3.52%)
NFLX   370.52 (-1.33%)
BAC   20.11 (-5.28%)
GILD   73.40 (-1.83%)
DIS   95.76 (-0.87%)
Log in

NYSE:CTLT - Catalent Stock Price, Forecast & News

$49.27
-2.68 (-5.16 %)
(As of 04/1/2020 11:06 AM ET)
Today's Range
$48.12
Now: $49.27
$50.34
50-Day Range
$36.95
MA: $51.19
$60.65
52-Week Range
$31.04
Now: $49.27
$68.78
Volume208,577 shs
Average Volume1.47 million shs
Market Capitalization$7.21 billion
P/E Ratio58.65
Dividend YieldN/A
Beta1.77
Catalent, Inc. provides delivery technologies and development solutions for drugs, biologics, and consumer and animal health products worldwide. It operates through four segments: Softgel Technologies, Biologics and Specialty Drug Delivery, Oral Drug Delivery, and Clinical Supply Services. The Softgel Technologies segment formulates, develops, and manufactures prescription and consumer soft capsules for use in a range of customer products, such as prescription drugs, over-the-counter medications, dietary supplements, unit-dose cosmetics, and animal health medicinal preparations. The Biologics and Specialty Drug Delivery segment formulates, develops, and manufactures small molecule and biologic drug products in prefilled syringes, vials and cartridges, blow-fill-seal unit doses, and injectable formats; develops biologic cell lines; manufactures biologic drug substances; and offers bioanalytical development and testing services. The Oral Drug Delivery segment formulates, develops, and manufactures oral dosage forms using proprietary and conventional drug delivery technologies, such as Zydis, OptiDose CR, OptiPact, OptiForm API and Solution Suite, Pharmatek SD Spray Drying, OptiMelt hot melt extrusion, Micron particle size reduction, and FlexDose; and provides stick pack formulation and filling, and analytical development and testing services. The Clinical Supply Services segment offers Manufacturing, packaging, labeling, storage, distribution, and inventory management for drugs and biologics clinical trials; FastChain demand-led clinical supply services; clinical e-solutions and informatics; and comparator sourcing services. The company serves pharmaceutical, biotechnology, and consumer health companies; and companies in other healthcare market segments, such as animal health and medical devices, as well as in cosmetics industries. Catalent, Inc. was founded in 2007 and is headquartered in Somerset, New Jersey.
Read More
Catalent logo

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
CUSIPN/A
Phone732-537-6200

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$2.52 billion
Cash Flow$3.23 per share
Book Value$11.54 per share

Profitability

Net Income$137.40 million

Miscellaneous

Employees12,300
Market Cap$7.21 billion
Next Earnings Date5/5/2020 (Estimated)
OptionableOptionable

Receive CTLT News and Ratings via Email

Sign-up to receive the latest news and ratings for CTLT and its competitors with MarketBeat's FREE daily newsletter.


Catalent (NYSE:CTLT) Frequently Asked Questions

How has Catalent's stock been impacted by COVID-19 (Coronavirus)?

Catalent's stock was trading at $46.05 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, CTLT stock has increased by 7.0% and is now trading at $49.27. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Catalent?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Catalent in the last year. There are currently 1 hold rating and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Catalent.

When is Catalent's next earnings date?

Catalent is scheduled to release its next quarterly earnings announcement on Tuesday, May 5th 2020. View our earnings forecast for Catalent.

How were Catalent's earnings last quarter?

Catalent Inc (NYSE:CTLT) posted its quarterly earnings data on Monday, February, 3rd. The company reported $0.45 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.39 by $0.06. The company earned $721.40 million during the quarter, compared to analyst estimates of $700.81 million. Catalent had a return on equity of 15.21% and a net margin of 5.44%. The firm's revenue was up 15.8% on a year-over-year basis. During the same quarter in the prior year, the firm posted $0.45 earnings per share. View Catalent's earnings history.

What guidance has Catalent issued on next quarter's earnings?

Catalent updated its FY 2020 Pre-Market earnings guidance on Monday, February, 3rd. The company provided EPS guidance of 1.92-2.06 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $1.97. The company issued revenue guidance of $2.87-2.95 billion, compared to the consensus revenue estimate of $2.85 billion.

What price target have analysts set for CTLT?

6 equities research analysts have issued 12-month price targets for Catalent's shares. Their forecasts range from $57.00 to $75.00. On average, they anticipate Catalent's stock price to reach $64.00 in the next year. This suggests a possible upside of 29.9% from the stock's current price. View analysts' price targets for Catalent.

Has Catalent been receiving favorable news coverage?

Media stories about CTLT stock have trended very negative on Wednesday, according to InfoTrie. InfoTrie ranks the sentiment of news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Catalent earned a news impact score of -3.0 on InfoTrie's scale. They also gave news coverage about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an impact on the company's share price in the next several days. View the latest news aboutCatalent.

Who are some of Catalent's key competitors?

What other stocks do shareholders of Catalent own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Catalent investors own include Alibaba Group (BABA), Energy Transfer LP Unit (ET), AT&T (T), Thermo Fisher Scientific (TMO), AbbVie (ABBV), CVS Health (CVS), Verizon Communications (VZ), NVIDIA (NVDA), Abbott Laboratories (ABT) and Pfizer (PFE).

Who are Catalent's key executives?

Catalent's management team includes the following people:
  • Mr. John R. Chiminski, Chairman & CEO (Age 55)
  • Mr. Wetteny N. Joseph, Sr. VP & CFO (Age 47)
  • Mr. Steven L. Fasman, Sr. VP, Gen. Counsel & Corp. Sec. (Age 56)
  • Mr. Jonathan Arnold, Pres of Oral Drug Delivery Bus. Unit (Age 53)
  • Mr. Alessandro Maselli, Pres & COO (Age 47)

What is Catalent's stock symbol?

Catalent trades on the New York Stock Exchange (NYSE) under the ticker symbol "CTLT."

How do I buy shares of Catalent?

Shares of CTLT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Catalent's stock price today?

One share of CTLT stock can currently be purchased for approximately $49.27.

How big of a company is Catalent?

Catalent has a market capitalization of $7.21 billion and generates $2.52 billion in revenue each year. The company earns $137.40 million in net income (profit) each year or $1.62 on an earnings per share basis. Catalent employs 12,300 workers across the globe. View additional information about Catalent.

What is Catalent's official website?

The official website for Catalent is http://www.catalent.com/.

How can I contact Catalent?

Catalent's mailing address is 14 SCHOOLHOUSE ROAD, SOMERSET NJ, 08873. The company can be reached via phone at 732-537-6200 or via email at [email protected]


MarketBeat Community Rating for Catalent (NYSE CTLT)

Community Ranking:  2.3 out of 5 (star star)
Outperform Votes:  583 (Vote Outperform)
Underperform Votes:  665 (Vote Underperform)
Total Votes:  1,248
MarketBeat's community ratings are surveys of what our community members think about Catalent and other stocks. Vote "Outperform" if you believe CTLT will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CTLT will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 4/1/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel